Medicenna CEO to Present at H.C. Wainwright Conference Amid Clinical Pipeline Advancements — Medicenna Therapeutics Corp.

Event summary

Medicenna CEO Dr. Fahar Merchant to present at H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026.
Bizaxofusp, Medicenna’s lead candidate, has been evaluated in over 130 patients across five clinical trials.
Company developing three clinical-stage programs targeting cancer, autoimmune, and inflammatory diseases.
Bizaxofusp holds Fast Track and Orphan Drug designations from FDA and EMA.

The big picture

Medicenna’s presentation comes as the immunotherapy sector faces increasing competition and regulatory scrutiny. The company’s ability to differentiate its Superkines platform will be critical in attracting investment and securing partnerships. With bizaxofusp’s Fast Track designation, Medicenna is positioning itself for potential accelerated approval, a key strategic advantage in the oncology space.

What we're watching

Clinical Progress: How Medicenna’s Phase 2b study in recurrent glioblastoma will impact bizaxofusp’s regulatory path.
Pipeline Execution: Whether Medicenna can sustain momentum across its three clinical-stage programs.
Investor Sentiment: The pace at which Medicenna can convert clinical data into investor confidence.